Bristol-Myers Squibb’s Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis in Phase 2 Trial 17/09/2018 Medications PRINCETON, N.J.–(BUSINESS WIRE)– September 12, 2018 — Bristol-Myers Squibb Company Read more